arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AGENUS INC

AGEN
$6.95 ▼ -0.54 (-7.28%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
47
Health
Weak
Neutral
auto_awesome

Analytical Summary

AGENUS INC demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $206.7M
Dividend Yield
Revenue Growth 10.4%
Op. Margin -17.7%
ROIC 8.9%
FCF / Share $-2.60
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.16
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$114.20M
↑ +10.4%
Net Income Profit after all expenses
$-3.08M
↑ +98.7%
Operating Margin Operating profit as % of sales
-17.7%
↑ +84.8% 11th
FCF / Share Free cash flow per share
$-2.60
↑ +64.9%
Long-Term Debt Long-term obligations
$44.66M
↑ +34.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
46
Financial Health
63
Cash Quality
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters